Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination

Immunization against the spike protein of SARS-CoV-2 reduces transmission and severe outcomes. However, little is known regarding the impact of immune-mediated diseases and immunosuppressive medications on the efficacy of vaccination. Vaccination immunity is transient, with breakthrough cases increasing at longer time intervals since the last dose. Although there are data on SARS-CoV-2 vaccine on early seroconversion in patients with inflammatory bowel disease (IBD), no data in the same cohort exist describing the durability of these antibodies over time. We sought to investigate the impact of IBD and its therapies on postvaccination antibody response and kinetics of immunogenicity decline, because these findings may better inform clinical guidelines and recommendations on precautions and booster vaccination.

Within a prospectively followed cohort of 195 patients with IBD who underwent 1 anti-S total Ab titer test at a nonpredetermined time, between April 15 and October 19, 2021, 185 had measured titers following both doses of the BNT162b2 (Pfizer, BioNTech; 60%; n = 111) or mRNA-1273 (Moderna; 35.1%; n = 65) vaccines, and 9 (4.6%) the JNJ-78436735 vaccine (Janssen Pharmaceutical Companies; excluded from analyses because of low sample size). All vaccine doses were given at recommended dosing intervals. We divided the patients into 2 main medication groups: vedolizumab (VDZ)/ustekinumab (UST)/mesalamine/budesonide/no therapy as group 1 and those on anti-tumor necrosis factor (TNF)-α ± immunomodulators as group 2. There were 7 patients on corticosteroids (prednisone ≥20 mg/day or equivalent within 30 days of dose 1) and 7 on tofacitinib, which we excluded from main analyses given low sample sizes. VDZ, UST, and mesalamine/budesonide/no therapy were grouped together to improve sample size because antibody titer trends among all 3 were similar on preliminary analysis (Supplementary Figure 1A). Furthermore, there was no difference in testing interval distribution between VDZ/UST and mesalamine/budesonide/no therapy. Median time between dose #2 and titer measurement was 126 days (interquartile range, 89–162), similarly distributed between mRNA vaccines (P = .799) and within vaccine-medication groups (P = .403; Supplementary Figure 1B). Among 169 mRNA-vaccine recipients, 46 had qualitative results (>2500 μ/mL, >250 μ/mL, <0.4 μ/mL) and were included only in dichotomous analyses.

We included patients with quantitative titers without prior history of COVID-19 (n = 121) in titer decay analyses. Geometric mean titer of anti-S total Ab among all patients was 306 μ/mL (95% confidence interval, 234–401). The overall mean log10(anti-S total Ab) was 5.72 (95% confidence interval, 5.45–5.99) without significant differences between vaccines (BNT162b2 5.83 ± 1.61 vs mRNA-1273 5.67 ± 1.51; Student t test; P = .6). One breakthrough COVID-19 infection was observed in a 69 year old with severely active Crohn’s disease treated with infliximab, 3 weeks after a titer of 13 μ/mL (measured 57 days after BNT162b2 dose #2). Patient characteristics and perivaccination disease activity approximated by surrogate markers (albumin, C-reactive protein, fecal calprotectin) are described in Supplementary Table 1.

Comparisons of mean log10(anti-S total Ab) across subgroups revealed significant differences between medication groups 1 and 2, in both BNT162b2 and mRNA-1273 recipients (Figure 1A). Comparisons among 4 arbitrarily selected titer thresholds, at different timepoints and overall, showed significantly lower proportions of patients in group 2 that mounted anti-S total Ab above each threshold, with statistically significant difference persisting up to anti-S total Ab ≥300 μ/mL for at least 4 months after dose #2, whereas comparisons after 6 months exhibited large numerical differences without reaching statistical significance because of sample size (Figure 1B).

There was significant decay observed in group 2 (n = 42; exponentiated decay coefficient [EDC] 1.8%/day; P = .012; estimated half-life, 38 days) and it was significantly faster (Δ-slope P = .045) than group 1 (n = 74; P = .058; EDC 0.05%/day; estimated half-life, 153 days), as shown in Figure 1C.

Figure 1D shows the differences between the 2 mRNA vaccines among patients receiving anti-TNF-α antagonist monotherapy, with graphical evidence of greater decay in BNT162b2 (n = 25; EDC 2.4%/day; P = .002; half-life, 28 days) compared with mRNA-1273 (n = 10; EDC 0.9%/day; P = .188; half-life, 76 days), and slope difference approaching significance (P = .109), despite relatively low sample size.
Four patients (2.3%; mean age, 63.3 years) had undetectable antibodies (measurement days: 7, 34, 104, 181; 3 BNT162b2, 1 mRNA-1273). Two of the BNT162b2 patients (1 on UST) and the mRNA-1273 patient (on UST and 6-mercaptopurine) were also receiving tacrolimus after solid-organ transplant. The fourth patient (BNT162b2, titer at day #181) was on adalimumab and on dialysis for end-stage renal disease.

These data demonstrate robust immunogenicity among patients with IBD to SARS-CoV-2 vaccination, with the notable exception of those on simultaneous transplant immunosuppressants, and are the first data to describe the kinetics of immunogenicity decay in this cohort. Although our cohort had only 1 vaccinated patient develop COVID-19, our breakthrough infection rate is likely underestimated because there was no predetermined testing at prespecified intervals, potentially missing asymptomatic carriers. Patients on anti-TNF-α ± immunomodulators had lower titers and more rapid decay than those on no immunosuppression/VDZ/UST.
Our findings are in line with the findings of Edelman-Klapper et al., where at a 4-week follow-up period, anti-TNF-α patients exhibited significantly lower anti-S IgG titers, together with lower neutralizing and inhibitory functions of anti-S IgG, when compared with non-anti-TNF-α-treated patients. Recent data by Aldrige et al. using the same titer assay, showed that a >500 μ/mL cutoff conferred 38% lower risk for breakthrough infection in the community setting (n = 197/8858; 2.2%; median follow-up, 4 months). Furthermore, earlier studies have shown that anti-S antibodies correlate with both neutralizing antibody titers and T-cell response, allowing extrapolation of the clinical usefulness of anti-S antibodies in conferring immunity against SARS-CoV-2. Additionally, initial titer response has been suggested to positively impact long-term immunity. The previously discussion, together with our findings, suggest that most patients with IBD still carry a theoretical risk of breakthrough infection after vaccination, but especially those on anti-TNF-α agents (<20% with anti-S total Ab ≥500 μ/mL at ≥2 months after dose #2). Furthermore, among the anti-TNF-α-treated patients, titer decay was 2.7 times faster in BNT162b2 vaccine recipients compared with the mRNA-1273 vaccine, thus potentially exposing to earlier breakthrough-infection risk. We thus agree that augmented vaccine dosing regimens as recommended by the Centers for Disease Control and Prevention may be needed for patients with IBD, especially those on anti-TNF-α agents and possibly BNT162b2 recipients, although more data are needed to confirm the latter.

Supplementary Material

Note: To access the supplementary material accompanying this article, please click here.

PARIS CHARILAOU, MD
CHRISTOPHER TRICARICO, MD
ROBERT BATTAT, MD

References
1. Baden LR, et al. N Engl J Med 2021;384:403–416.
2. Polack FP, et al. N Engl J Med 2020;383:2603–2615.
3. Keehner J, et al. N Engl J Med 2021;385:1330–1332.
4. Keehner J, et al. N Engl J Med 2021;384:1774–1775.
5. Edelman-Klapper H, et al. Gastroenterology 2021.
6. Aldridge RW, et al. medRxiv 2021:2021.11.05.21265968.
7. Ni L, et al. Immunity 2020;52:971–977.
8. Peng Y, et al. Nat Immunol 2020;21:1336–1345.
9. Wang Y, et al. J Clin Invest 2020;130:5235–5244.
10. Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. Available at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#considerations-covid19-vax-immunocompromised. Accessed October 27, 2021.

Reprint requests
Address requests for reprints to: Dana J. Lukin, MD, PhD, 420 East 70th Street, LH-508, New York, New York 10021. e-mail: dj9010@med.cornell.edu; fax: (718) 798-6408.

Conflicts of interest
These authors disclose the following: Ellen J. Scherl received grant/research support from Abbott (AbbVie), AstraZeneca, Crohn’s and Colitis Foundation of America (CCFA), Janssen Research & Development, Johns Hopkins University, National Institute of Diabetes and Digestive and Kidney, National Institutes of Health, New York Crohn’s Foundation, Pfizer, UCSF–CCFA Clinical Research Alliance, Genentech, Seres Therapeutics, and Celgene Corporation; is a consultant/advisory board member for AbbVie, CCFA, Entera Health, Evidera, Gl Health Foundation, Janssen, Protagonist Therapeutics, Seres Health, Takeda, and Bristol Myers Squibb; is a stock shareholder with Gilead; and received honoraria from Gilead Foundation for nonbranded speaker’s bureau and Janssen for nonbranded speaker’s bureau. Randy S. Longman is a consultant for Pfizer; Dana J. Lukin is a consulting/advisory board member for AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, Palatin Technologies, and Pfizer; data safety monitoring board member for WuXi AppTec; scientific advisory board member for PSI; and received grant support from AbbVie, Janssen, Takeda, and Kenneth Rainin Foundation. The remaining authors disclose no conflicts.

Funding
This work was supported by an internal funding mechanism, the Jill Roberts Center for IBD Pilot Award (DJL).
Supplementary Methods

Data were collected retrospectively using the Data-Mart Inflammatory Bowel Disease (IBD) database of New York-Presbyterian Hospital Weill Cornell Medicine, from April 1, 2021 to October 19, 2021. We collected all patients with IBD who had “SARS-CoV-2 Semi-Quantitative Total Antibody Spike” test (LabCorp test #164090, an electrochemiluminescence immunoassay). The data were then quality controlled via manual chart review. The study was approved by the institutional review board.

Missing values were not imputed because of sample size limitation (n = 185), to ensure data validity. Continuous variables were analyzed using the Student t test and Mood medians test for normally and non-normally distributed data, respectively. Categorical variables were analyzed using chi-square or Fisher exact tests. Multiple comparisons were done using 1-way analysis of variance, with Bonferroni correction to adjust for alpha-error inflation. The main outcome of interest, anti-S total Ab titer, was presented as a geometric mean titer or log-transformed (with base e), given its log-normal distribution and to allow linear modelling on its otherwise nonnormally distributed residuals should be left untransformed. Robust linear regression, which is robust to potential outliers and thus allowing to include all available data, was used to fit linear trends among various comparison groups to assess the linear ln(anti-S total Ab) decay since dose #2 of vaccination. By extension, the exponentiated decay coefficients represent the percent change from the geometric mean titer. STATA MP version 15 was used for all analyses (Stata Corp, College Station, TX). All comparison were deemed significant a priori at P < .05, unless otherwise stated.
Supplementary Figure 1. (A) Days since dose #2 among non-anti-TNF-α medication groups. Preliminary analysis of slopes and intercepts (ie, theoretical immediate post-vaccination titers) was nonsignificantly different among UST only, VDZ only, and mesalamine/budesonide/no therapy groups. (B) Days since dose #2 distribution between vaccine-medication groups. The median time between second dose and titer measurement was 126 days (interquartile range, 89–162) and similarly distributed between mRNA vaccines ($P = .799$) and within vaccine-medication groups ($P = .403$).
**Supplementary Table 1.** Characteristics of IBD Patients Who Received mRNA-Vector Vaccines

| Variable                          | mRNA-1273 (n = 65 (36.9%)) | BNT162b2 (n = 111 (63.1%)) | Overall n = 176 | P value |
|-----------------------------------|-----------------------------|-----------------------------|-----------------|---------|
| **Age at dose #1, y**             | 47.5 ± 17.4 (43; 33–63)     | 47.1 ± 15.3 (47; 33–59)     | 47.3 ± 16.0 (47; 33–60.5) | .890    |
| Female                            | 42 (64.6)                   | 77 (69.4)                   | 119 (67.6)      | .515    |
| Prior history of COVID-19         | 6 (9.2)                     | 10 (9)                      | 16 (9.1)        | .961    |
| Crohn’s disease                   | 43 (66.2)                   | 69 (62.7)                   | 112 (64)        | .648    |
| Ulcerative colitis extent         |                             |                             |                 |         |
| E1                                | 1 (4.6)                     | (0)                         | 1 (1.6)         | .345    |
| E2                                | 9 (40.9)                    | 20 (50)                     | 29 (46.8)       |         |
| E3                                | 12 (54.6)                   | 20 (50)                     | 32 (51.6)       |         |
| Ulcerative colitis severity       |                             |                             |                 |         |
| S0                                | 3 (13.6)                    | 7 (17.5)                    | 10 (16.1)       | .971    |
| S1                                | 8 (36.4)                    | 15 (37.5)                   | 23 (37.1)       |         |
| S2                                | 4 (18.2)                    | 6 (15)                      | 10 (16.1)       |         |
| S3                                | 7 (31.8)                    | 12 (30)                     | 19 (30.7)       |         |
| Crohn’s disease classification    |                             |                             |                 |         |
| A1                                | 5 (11.6)                    | 10 (14.7)                   | 15 (13.5)       | .026    |
| A2                                | 23 (53.5)                   | 49 (72.1)                   | 72 (64.9)       |         |
| A3                                | 15 (34.9)                   | 9 (13.2)                    | 24 (21.6)       |         |
| L1                                | 10 (23.3)                   | 27 (39.7)                   | 37 (33.3)       | .073    |
| L2                                | 8 (18.6)                    | 11 (16.2)                   | 19 (17.1)       | .741    |
| L3                                | 25 (58.1)                   | 30 (44.1)                   | 55 (49.6)       | .150    |
| L4                                | 2 (4.7)                     | 1 (1.5)                     | 3 (2.7)         | .314    |
| B1                                | 17 (100)                    | 30 (96.8)                   | 47 (97.9)       | .454    |
| B2                                | 18 (100)                    | 20 (95.2)                   | 38 (97.4)       | .348    |
| B3                                | 11 (100)                    | 20 (95.2)                   | 31 (96.9)       | .462    |
| Perianal disease                  | 7 (100)                     | 12 (92.3)                   | 19 (95)         | .452    |
| Biologics/SM within 3 mo of dose #1 |                 |                             |                 |         |
| No biologic/SM                    | 20 (30.8)                   | 35 (31.5)                   | 55 (31.3)       | .474    |
| IFX/ADA/CTZ                       | 14 (21.5)                   | 33 (29.7)                   | 47 (26.7)       |         |
| UST                               | 22 (33.9)                   | 25 (22.5)                   | 47 (26.7)       |         |
| VDZ                               | 6 (9.2)                     | 14 (12.6)                   | 20 (11.4)       |         |
| Tofacitinib                       | 3 (4.6)                     | 4 (3.6)                     | 7 (4)           |         |
| Prednisone ≥20 mg/day within 30 days of 1st dose | 4 (6.2) | 3 (2.7) | 7 (4) | .258 |
| Immunomodulators                  | 11 (16.9)                   | 7 (8.3)                     | 18 (10.2)       | .025    |
| Anti-TNF-α + IMM                  | 2 (14.3)                    | 2 (6.1)                     | 4 (8.5)         | .355    |
### Supplementary Table 1. Continued

| Variable | mRNA-1273 | BNT162b2 | Overall n = 176 | P value |
|----------|-----------|-----------|-----------------|---------|
| **Vaccination-related data** | | | | |
| Above median anti-S total Ab (≥477 μ/mL) | 46 (70.8) | 66 (59.5) | 112 (63.6) | .132 |
| Vaccine nonresponder | 1 (1.5) | 3 (2.7) | 4 (2.3) | .617 |
| Titer testing interval (days since dose #2) | 131 ± 60 (145; 81–174) | 124 ± 51 (123; 91–161) | 126 ± 54 (126; 89–162) | .441 |
| Anti-S total Ab titer (μ/mL) (n = 128) | 759.8 ± 713.0 (GM: 340; 593–1256) | 610.6 ± 601.8 (GM: 291; 445–982) | 659.6 ± 641.5 (GM: 305; 477–1107) | .225 |
| ln(anti-S total Ab) titer (μ/mL) (n = 128) | 5.83 ± 1.61 (6.38; 4.67–7.14) | 5.67 ± 1.51 (6.10; 4.94–6.88) | 5.72 ± 1.54 (6.17; 4.82–7.01) | .661 |
| **Disease activity markers** | | | | |
| Any albumin <3.5 mg/dL (from 60 d before dose #1 up to titer date) | 15 (25.4) | 15 (16.3) | 30 (19.9) | .171 |
| Mean albumin (g/dL; from 60 d before dose #1 up to titer date) (n = 151) | 3.91 ± 0.45 (3.9; 3.7–4.2) | 4.06 ± 0.47 (4.2; 3.85–4.4) | 4.00 ± 0.47 (4.1; 3.8–4.3) | .042 |
| Any FCP ≥250 μg/g (from 60 d before dose #1 up to titer date) | 16 (57.1) | 17 (50) | 33 (53.2) | .575 |
| Mean FCP (μg/g; from 60 d before dose #1 up to titer date) (n = 62) | 397.2 ± 471.2 (291; 77–492) | 447.1 ± 671.6 (205; 43–437) | 424.6 ± 585.6 (239; 66.5–486) | .741 |
| Any CRP ≥1 mg/dL (from 30 d before dose #1 up to titer date) | 18 (40) | 12 (16.4) | 30 (25.4) | .004 |
| Mean CRP (mg/dL; from 30 d before dose #1 up to titer date) (n = 59) | 1.02 ± 1.84 (0.4; <0.04–1.3) | 0.68 ± 1.72 (<0.04; <0.04–0.4) | 0.81 ± 1.77 (<0.04; <0.04–0.80) | .309 |

NOTE. Values are n (%) or mean ± SD (median; IQR). ADA, adalimumab; anti-S, anti-spike; CRP, C-reactive protein; CTZ, certolizumab; FCP, fecal calprotectin; GM, geometric mean; IBD, inflammatory bowel disease; IFX, infliximab; IMM, immunomodulators; IQR, interquartile range; ln, natural logarithm; SD, standard deviation; SM, small molecule; TNF, tumor necrosis factor; UST, ustekinumab; VDZ, vedolizumab.